Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MHLW Mulls Legal Disclosure of Drug Makers’ Clinical Research Payments
May 13, 2015
- Chuikyo to Begin Open Debates on Cost-Effectiveness Case Study from Late May: Official
May 12, 2015
- Govt to Hear Opinions from Trade, Professional Groups on Generic Promotion
May 12, 2015
- Applications for Sakigake Review System May Be Accepted from Early Stage of Development: Official
May 12, 2015
- Editor’s Pick: Five Healthcare News Headlines for April 20 - May 10
May 11, 2015
- PMDA Evaluating Xalkori for Risk of Cardiac Failure
May 11, 2015
- Chuikyo to Discuss Listing of Gilead’s Sovaldi on May 13; Listing Could Take Place This Month
May 11, 2015
- 10-Year Reexamination Period Possible for Repositioned Drugs under Sakigake System: Official
May 8, 2015
- DPC Hospitals with Generic Use Rates Above 60% More Than Doubled
May 1, 2015
- MHLW to Give Medical Subsidies for 196 “Designated Intractable Diseases” from July
May 1, 2015
- PAFSC 1st Committee Recommends Irribow Use in Females
May 1, 2015
- Submission of CDISC-Based Clinical Data Required from October 2016: Notification
April 30, 2015
- Thrombocytopenia Added to Clinically Significant ADR List for Januvia, Glactiv: Safety Bulletin
April 30, 2015
- Scrutinize Purpose of Price Maintenance Premium for New Drugs: MOF
April 28, 2015
- MOF Presses for 80% Generic Share Target by FY2017
April 28, 2015
- Number of Topics Discussed by PAFSC Second Committee Exceeds that of First Committee for 1st Time in 10 Years: Jiho Tally
April 28, 2015
- Patient-Initiated Mixed Care Used Only When Compassionate Access Can’t Be Applied: Minister
April 28, 2015
- PAFSC Second Committee Backs Approval of Add’l Indication for PegIntron
April 27, 2015
- AMED, JPMA Discussing Joint Use of Compounds, with Policy Announcement Expected in Early June: Dr Suematsu of AMED
April 27, 2015
- MHLW Looking into Drug Maker Payments to PAFSC Members: Shiozaki
April 24, 2015
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…